Search PubMed⌕ Search

Biomedical subjects

E John

Publications and source records attributed to E John.

111 records · Page 7Linked to original sources

Retinopathy of prematurity in infants less than 29 weeks' gestation: 3 1/2 years pre- and postsurfactant.

OBJECTIVE: To determine the effects of surfactant on retinopathy of prematurity (ROP). DESIGN: We compared infants for 3 1/2 years both before and after the introduction of surfactant in our neonatal intensive care unit (NICU) using prospectively collected data. Exogenous surfactant (Exosurf) was introduced into our NICU on July 1, 1991. METHODS: We compared the incidence and severity of ROP in two groups of infants born at less than 29 weeks' gestation who required cryo- or laser therapy. Premature infants born during the first 3 1/2 years following the introduction of surfactant were compared with those born during the 3 1/2-year period prior to its introduction. The infants were examined by one ophthalmologist (J.K.) and classified according to the International Classification of ROP. RESULTS: A total of 124 infants born presurfactant and 152 infants born postsurfactant were examined for the presence of ROP. No significant difference between the two groups regarding any stage of ROP or the necessity for treatment was found. In infants of less than 27 weeks' gestation, a significant reduction in the number requiring cryo- or laser therapy was noted (12 of 48 examined [25.0%] vs 6 of 62 examined [9.7%], respectively; P < 0.05). This decreased need for treatment, however, was found in infants without hyaline membrane disease who did not receive surfactant. CONCLUSION: Exosurf has had no significant impact on the incidence or severity of ROP. Due to its effect on improved survival rates, the surfactant produces a larger proportion of infants at risk of developing ROP. Other changes in NICU protocol may be causing a reduction in the incidence of severe ROP.

Cryosurgery↗

Elimination of vancomycin by continuous arteriovenous hemofiltration.

Continuous arteriovenous hemofiltration (CAVH) is being used increasingly in pediatric patients with acute renal failure and/or other fluid and electrolyte imbalances. At times, vancomycin may be concurrently given for sepsis therapy. We evaluated the removal of vancomycin by CAVH in a 15-month-old male child with renal failure who was receiving the drug for suspected infection of an arterial catheter. Two separate CAVH treatments were performed with polysulfone membranes. Serum samples and ultrafiltrate outflow (n = 6) were collected over 79 h for vancomycin concentration determination. The mean vancomycin concentration in the ultrafiltrate was 90.4 +/- 5.4% of those of the serum. 0.53-1.11 mg of the drug was removed per hour by CAVH at serum concentrations of 12.4-25.4 mg/l. CAVH vancomycin clearance was 0.039-0.050 liter/h. The CAVH drug clearances accounted for 66.2% of the total vancomycin clearance. CAVH is thus a major route of vancomycin elimination. Dosage adjustment and serum concentration monitoring are necessary in patients undergoing CAVH while receiving vancomycin therapy.

Acute Kidney Injury↗